Dailypharm Live Search Close

Use of Evusheld extended to the severely immunocompromised

By Kim, Jung-Ju | translator Alice Kang

22.11.15 19:29:23

°¡³ª´Ù¶ó 0
COVID-19 Vaccination Response Promotion Team expands subjects as of the 14th of this month



The COVID-19 Vaccination Response Promotion Team (Head: KDCA Commissioner Kyung-Ran Baek) announced that it had expanded the eligibility of Evusheld as of the 14th to protect the severely immunocompromised from the next wave of COVID-19 outbreak that may arise in the winter season.

With the expansion, blood cancer patients, transplant recipients, and people with congenital immunodeficiency who are severely immunocompromised; those with solid cancer, HIV, or rheumatism following deliberation by the Infectious Disease Control Committee; and patients who are receiving serious immunosuppressive treatment such as chemotherapy or B-cell depletion treatment regardless of disease are eligible for Evusheld.
Kim, Jung-Ju(jj0831@dailypharm.com)
If you want to see the full article, please JOIN US (click)